Skip to main content


Log in

New agents, new rashes: An update on skin complications from cancer chemotherapy

  • Published:
Current Oncology Reports Aims and scope Submit manuscript


Several new drugs have emerged as effective antineoplastic agents in the past 5 years. Many of these drugs cause rashes. For example, rash is one of the two most frequent adverse events that occur in cancer patients prescribed epidermal growth factor receptor inhibitors. This review discusses rash in the context of epidermal growth factor receptor inhibitors and in the context of a few other recently approved cancer drugs. It also embarks on a brief discussion of issues that investigators must face when designing clinical trials aimed at rash palliation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Barankin B, DeKoven J: Psychological effect of common skin diseases. Can Fam Physician 2002, 48:712–716.

    PubMed  Google Scholar 

  2. Lasek RJ, Chren MM: Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998, 134:454–458.

    Article  PubMed  CAS  Google Scholar 

  3. Shepherd FA, Rodrigues PereiraJR, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123–132.

    Article  PubMed  CAS  Google Scholar 

  4. Saltz L, Rubin MS, Hochster H, et al.: Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Clin Cancer Res 2001, 7:3766s (abstract 559).

    Google Scholar 

  5. Perez-Solar R, Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005 23:5235–5246. This study highlights data that suggest epidermal growth factor inhibitor-induced rashes may predict better patient outcome.

    Article  Google Scholar 

  6. Albanell J, Rojo F, Averbuch S, et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2001, 20:110–124.

    Article  Google Scholar 

  7. Van DoornR, Kirtschig G, Scheffer E, et al.: Follicular and epidermal alterations in patients treated with ZD1839, an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002, 147:598–601.

    Article  PubMed  Google Scholar 

  8. Hoff PM: Capecitabine as first line treatment for metastatic colorectal cancer (CRC): integrated results of 1201 patients from 2 randomized phase III studies. On behalf of the Capecitabine CRC Study Group [abstract]. Ann Oncol 2000, 11(Suppl 4):60.

    Google Scholar 

  9. Nowacki M, Kroning H, Cervantes A, et al.: Improved safety of capecitabine Vs bolus 5FU?Leucovorin (LV) as adjuvant therapy for colon cancer (X-ACT phase III study) Eur J Cancer 2003, 1(Suppl 5):S326.

    Google Scholar 

  10. Blum J, Jones S, Buzdar A, et al.: Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: updated results and analysis of dose modification [abstract]. Eur J Cancer 2001b, 37(Suppl 6):s190.

    Article  Google Scholar 

  11. Blum Jl, Dieras V, Lo Russo PM, et al.: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer 2001, 92:1759–1768.

    Article  PubMed  CAS  Google Scholar 

  12. O’Shaughnessy J, Blum J, Moiseyenko V, et al.: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF(cyclophosphamide, methotrexate and 5-fluorouracil) as first line therapy for advanced/metastatic breast cancer. Ann Oncol 2001, 12:1247–1254.

    Article  CAS  Google Scholar 

  13. Fumoleau P, Largillier P, Clippe C, et al.: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline and taxane pretreated metastatic breast cancer. Eur J Cancer 2004, 40:536–542.

    Article  PubMed  CAS  Google Scholar 

  14. Maung K: Capecitabine/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer: results of a phase III study. Clin Breast Cancer 2003, 3:375–377.

    Google Scholar 

  15. Reichardt P, von Mickwitz G, Thuss-Patience PC, et al.: Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003, 14:1227–1233.

    Article  PubMed  CAS  Google Scholar 

  16. Lassere Y, Hoff P: Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004, 8(Suppl 1):S31-S40.

    Article  PubMed  Google Scholar 

  17. Lopez AM, Wallace L, Dorr RT, et al.: Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999, 44:303–306.

    Article  PubMed  CAS  Google Scholar 

  18. Lauman MK, Mortimer J: Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine [abstract]. Proc ASCO 1999, 20:392a.

    Google Scholar 

  19. Demetri GD, von MehrenM, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472–480.

    Article  PubMed  CAS  Google Scholar 

  20. Lammie A, Drojnak M, Gerald W, et al.: Expression of c-kit and kit ligands proteins in normal human tissues. J Histochem Cytochem 1994, 42:1417–1425.

    PubMed  CAS  Google Scholar 

  21. Liden A, Berg A, Nedrebo T, et al.: Platelet-derived growth factor BB-mediated normalization of dermal interstitial fluid pressure after mast cell degranulation depends on beta3 but not beta1 integrins. Circ Res 2006, 98:635–641.

    Article  PubMed  CAS  Google Scholar 

  22. Valeyrie L, Bastuji-Garin S, Revuz J, et al.: Adverse cutaneous reactions to imatinib in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003, 48:201–206. This study provides prospective data that focuses specifically on rash development with imatinib.

    Article  PubMed  Google Scholar 

  23. Rule SAJ, O’Brien SG, Crossman LC: Managing cutaneous reactions to imatinib. Blood 2002, 100:3434.

    Article  PubMed  CAS  Google Scholar 

  24. Molina JR, Adjei AA: The role of pemetrexed in lung cancer therapy. Clin Lung Cancer 2003, 5:21–27.

    Article  PubMed  CAS  Google Scholar 

  25. Hanna N, Shepherd FA, Fossella FV, et al.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589–1597.

    Article  PubMed  CAS  Google Scholar 

  26. Hazarika M, White RM, Booth BP, et al.: Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005, 11:982–992.

    PubMed  CAS  Google Scholar 

  27. Lopes G, Vincek V, Raez LE: Pemetrexed-associated urticarial vasculitis. Lung Cancer 2006, 51:247–249.

    Article  PubMed  Google Scholar 

  28. Hureaux J, Le Guen Y, Tuchais C, et al.: Radiation recall dermatitis with pemetrexed. Lung Cancer 2005, 50:255–258. To our knowledge, this paper is the first to describe radiation recall with pemetrexed. It provides an important reminder on the need to monitor patients carefully for rash development.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Aminah Jatoi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patiyil, S., Chan, S.N. & Jatoi, A. New agents, new rashes: An update on skin complications from cancer chemotherapy. Curr Oncol Rep 8, 269–274 (2006).

Download citation

  • Issue Date:

  • DOI: